Emerging Treatments in Cystic Fibrosis

@article{Jones2012EmergingTI,
  title={Emerging Treatments in Cystic Fibrosis},
  author={Andrew M. Jones and Jennifer Helm},
  journal={Drugs},
  year={2012},
  volume={69},
  pages={1903-1910}
}
There are a number of potential drugs for the treatment of cystic fibrosis (CF) currently undergoing clinical studies. A number of antibacterials formulated for delivery by inhalation are at various stages of study; these include dry-powder inhaler versions of colistin, tobramycin and ciprofloxacin, and formulations of azteonam, amikacin, levofloxacin, ciprofloxacin and fosfomycin/tobramycin for nebulization. Clinical trials of anti-inflammatory agents, including glutathione, phosphodiesterase… 
New and Emerging Treatments for Cystic Fibrosis
TLDR
Some of the potential challenges being encountered by research and clinical teams in developing and delivering treatments for cystic fibrosis are discussed and some of the exciting emerging therapies presently under evaluation in clinical trials are highlighted.
Cystic fibrosis therapeutics: the road ahead.
TLDR
The breadth of candidate treatments currently in development, as well as the recent progress in CF therapies reflected by the evolution of the therapeutics pipeline over the past few years, are reviewed to build upon the optimism and anticipation generated by the recent success of Kalydeco.
Inhalation of macrolides: a novel approach to treatment of pulmonary infections.
Systemic antibiotic treatment is established for many pulmonary diseases, e.g., cystic fibrosis (CF), bronchiectasis and chronic obstructive pulmonary disease (COPD) where recurrent bacterial
Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine
TLDR
AZLI is a new therapy that is safe and effectively improves respiratory symptoms and FEV1 in patients with CF and was recently approved for use in CF patients in Australia and the USA and conditionally approved in Canada and the European Union.
Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
TLDR
TIP administered via the T-326 Inhaler is an effective antipseudomonal agent with non-inferior efficacy and generally similar tolerability to that of nebulized TIS in CF patients with chronic P. aeruginosa infection.
Pulmonary Disease in Cystic Fibrosis
THERAPEUTIC DEVELOPMENT FOR CYSTIC FIBROSIS
TLDR
The results of in vitro studies performed are reported to better define the mechanism underpinning this imaging-based outcome measurement and define its utility and limitations.
Genetics and Pathophysiology of Cystic Fibrosis
Airway-Rehydrating Agents for the Treatment of Cystic Fibrosis: Past, Present, and Future
TLDR
Hypertonic saline is the primary airway-rehydrating agent used in the treatment of CF and inhaled mannitol may become an alternative to hypertoni saline since it is faster and easier to administer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
A phase I trial of intranasal Moli1901 for cystic fibrosis.
TLDR
Moli1901 stimulates chloride transport in normal and CF nasal epithelia in vivo, but may have a shorter duration of action in CF participants, according to a single-blind, randomized, placebo-controlled, dose-escalation study.
Safety and Efficacy of Recombinant Alpha1‐Antitrypsin Therapy in Cystic Fibrosis
TLDR
It is demonstrated that nebulized rAAT is safe and well‐tolerated, but has a limited effect on NE activity and other markers of inflammation.
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial
TLDR
AZM in adults with CF significantly improved QOL, reduced CRP levels and the number of respiratory exacerbations, and reduced the rate of decline in lung function, suggesting long term AZM may have a significant impact on morbidity and mortality in patients with CF.
Inhalation of Moli1901 in patients with cystic fibrosis.
TLDR
The inhalation of Moli1901 up to a total cumulative dose of 12.5 mg appears to be safe in adult patients with CF and had a sustained beneficial effect on pulmonary function, which supports further studies of its efficacy in CF patients.
Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa
TLDR
The 4-week administration of a highly concentrated TSI significantly improved pulmonary function and microbiologic outcome compared with placebo and was well tolerated.
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
TLDR
Azithromycin treatment was associated with improvement in clinically relevant end points and should be considered for patients with CF who are 6 years or older and chronically infected with P aeruginosa.
Macrolide antibiotics for cystic fibrosis.
TLDR
This review aimed to test the hypotheses that macrolide antibiotics, whilst not directly active against Pseudomonas aeruginosa, may have indirect actions against this bacteria and assess the optimal type, dose and duration of Macrolide therapy.
Clinical trials in cystic fibrosis.
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
TLDR
In a 24-week study of patients with cystic fibrosis, intermittent administration of inhaled tobramycin was well tolerated and improved pulmonary function, decreased the density of P. aeruginosa in sputum, and decreased the risk of hospitalization.
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
TLDR
Although generally well-tolerated with no significant adverse effects, there was no evidence of significant clinical benefit in primary outcomes in participants receiving these treatments, and further research is required to investigate the potential role of these medications in improving the outcomes of people with cystic fibrosis.
...
1
2
3
4
5
...